Kevin Joseph Harrington

This paper shows that intratumoural oncolytic HSV-1 reprograms systemic immunity by inducing specific CD8 T cell populations that correlate with clinical response to immunotherapy.

This study evaluates a second-generation STING agonist, BI-1703880, showing that combining it with radiotherapy enhances antitumour immunity and immune memory.

This study shows that chemoradiotherapy (CRT) in head and neck cancer promotes clonal dominance of progenitor-exhausted CD8+ T-cells compared to radiotherapy alone.

This paper introduces CanonicalTockySeq to analyze T-cell fate decisions over time in immunotherapy, showing that effective treatment correlates with reduced antigen engagement and exhaustion signaling.

The paper identifies neuronal mimicry in cancer-associated fibroblasts driven by calcium waves, leading to immune exclusion, and shows that blocking this process restores immune control.

This study shows that radiation-induced podoplanin-positive fibroblasts limit CD8+ T-cell access to tumour cells, reducing radiotherapy effectiveness, and that disrupting PDPN signaling enhances tumour control.

This study shows ARID1A deficiency increases sensitivity to the G4 ligand pyridostatin due to impaired DNA repair, highlighting a role for ARID1A in G4 ligand-induced DNA damage responses.

This paper identifies PARP inhibitors as sensitizers for oncolytic reovirus by enhancing DISC-mediated apoptosis and NF-kappa B-driven immune responses.

This study shows that combining oncolytic Maraba virus with PD-1 blockade overcomes resistance in advanced melanoma with a cold tumor microenvironment.

The paper identifies 4-1BB as a potential immunotherapy target in undifferentiated pleomorphic sarcoma by analyzing patient cohorts and TCGA data.